Tacatuzumab-Y-90

N/A

Report date: 2025/11/24 17:27:48

Base Information

Drug NameTacatuzumab-Y-90

Drug Alias NameIMMU-105AFP-Cide Y-90

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedRadiation-emitting products > Nuclides > Yttrium > 90YRadiation-emitting products > Radionuclide Drug Conjugates +[5]

Mechanisms of ActionIonising radiation emittersAlpha-fetoprotein modulators

TargetsAlpha-fetoprotein

Therapy Area/IndicationsCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesImmunomedics

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesImmunomedics Inc

Active IndicationsN/A

Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A